Datapoint: Yescarta Scores Follicular Lymphoma Nod

The FDA on March 5 approved Gilead Sciences’ Yescarta for the treatment of relapsed or refractory follicular lymphoma in patients that have not responded to at least two prior treatments, a feat unmatched by its CAR-T rivals Kymriah and Breyanzi. Under the medical benefit, Yescarta is covered for 32% of all insured lives for the treatment of diffuse large B-cell lymphoma. A further 41% of covered lives have medical benefit access to Yescarta with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/10/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 6

Datapoint: Moda Health to Expand to Idaho

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today